1. Immunogenicity and Protective Efficacy of a Single Intranasal Dose Vectored Vaccine Based on Sendai Virus (Moscow Strain) against SARS-CoV-2 Variant of Concern.
- Author
-
Kochneva, Galina V., Kudrov, Gleb A., Zainutdinov, Sergei S., Shulgina, Irina S., Shipovalov, Andrei V., Zaykovskaya, Anna V., Borgoyakova, Mariya B., Starostina, Ekaterina V., Bodnev, Sergei A., Sivolobova, Galina F., Grazhdantseva, Antonina A., Ivkina, Daria I., Zadorozhny, Alexey M., Karpenko, Larisa I., and P'yankov, Oleg V.
- Subjects
SARS-CoV-2 Delta variant ,SENDAI virus ,INTRANASAL administration ,GOLDEN hamster ,SARS-CoV-2 - Abstract
The mouse paramyxovirus Sendai, which is capable of limited replication in human bronchial epithelial cells without causing disease, is well suited for the development of vector-based intranasal vaccines against respiratory infections, including SARS-CoV-2. Using the Moscow strain of the Sendai virus, we developed a vaccine construct, Sen-Sdelta(M), which expresses the full-length spike (S) protein of the SARS-CoV-2 delta variant. A single intranasal delivery of Sen-Sdelta(M) to Syrian hamsters and BALB/c mice induced high titers of virus-neutralizing antibodies specific to the SARS-CoV-2 delta variant. A significant T-cell response, as determined by IFN-γ ELISpot and ICS methods, was also demonstrated in the mouse model. Mice and hamsters vaccinated with Sen-Sdelta(M) were well protected against SARS-CoV-2 challenge. The viral load in the lungs and nasal turbinates, measured by RT-qPCR and TCID
50 assay, decreased dramatically in vaccinated groups. The most prominent effect was revealed in a highly sensitive hamster model, where no tissue samples contained detectable levels of infectious SARS-CoV-2. These results indicate that Sen-Sdelta(M) is a promising candidate as a single-dose intranasal vaccine against SARS-CoV-2, including variants of concern. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF